Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 3
2008 3
2009 5
2010 9
2011 12
2012 13
2013 14
2014 7
2015 11
2016 6
2017 14
2018 10
2019 8
2020 10
2021 12
2022 16
2023 14
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

156 results

Results by year

Filters applied: . Clear all
Page 1
Health-related quality of life during the COVID-19 pandemic: The impact of restrictive measures using data from two Dutch population-based cohort studies.
van Hagen CCE, Huiberts AJ, Mutubuki EN, de Melker HE, Vos ERA, van de Wijgert JHHM, van den Hof S, Knol MJ, van Hoek AJ. van Hagen CCE, et al. Among authors: knol mj. PLoS One. 2024 Mar 18;19(3):e0300324. doi: 10.1371/journal.pone.0300324. eCollection 2024. PLoS One. 2024. PMID: 38498510 Free PMC article.
Effectiveness of Omicron XBB.1.5 vaccine against infection with SARS-CoV-2 Omicron XBB and JN.1 variants, prospective cohort study, the Netherlands, October 2023 to January 2024.
Huiberts AJ, Hoeve CE, de Gier B, Cremer J, van der Veer B, de Melker HE, van de Wijgert JH, van den Hof S, Eggink D, Knol MJ. Huiberts AJ, et al. Among authors: knol mj. Euro Surveill. 2024 Mar;29(10):2400109. doi: 10.2807/1560-7917.ES.2024.29.10.2400109. Euro Surveill. 2024. PMID: 38456217 Free PMC article.
Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Alpha- and Delta-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021.
Rose AM, Nicolay N, Sandonis Martín V, Mazagatos C, Petrović G, Niessen FA, Machado A, Launay O, Denayer S, Seyler L, Baruch J, Burgui C, Loghin II, Domegan L, Vaikutytė R, Husa P, Panagiotakopoulos G, Aouali N, Dürrwald R, Howard J, Pozo F, Sastre-Palou B, Nonković D, Knol MJ, Kislaya I, Luong Nguyen LB, Bossuyt N, Demuyser T, Džiugytė A, Martínez-Baz I, Popescu C, Duffy R, Kuliešė M, Součková L, Michelaki S, Simon M, Reiche J, Otero-Barrós MT, Lovrić Makarić Z, Bruijning-Verhagen PC, Gomez V, Lesieur Z, Barbezange C, Van Nedervelde E, Borg ML, Castilla J, Lazar M, O'Donnell J, Jonikaitė I, Demlová R, Amerali M, Wirtz G, Tolksdorf K, Valenciano M, Bacci S, Kissling E; I-MOVE-COVID-19 hospital study team; VEBIS hospital study team; Members of the I-MOVE-COVID-19 and VEBIS hospital study teams (in addition to the named authors). Rose AM, et al. Among authors: knol mj. Euro Surveill. 2023 Nov;28(47):2300186. doi: 10.2807/1560-7917.ES.2023.28.47.2300186. Euro Surveill. 2023. PMID: 37997666 Free PMC article.
Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Omicron-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021 to 2022.
Rose AM, Nicolay N, Sandonis Martín V, Mazagatos C, Petrović G, Baruch J, Denayer S, Seyler L, Domegan L, Launay O, Machado A, Burgui C, Vaikutyte R, Niessen FA, Loghin II, Husa P, Aouali N, Panagiotakopoulos G, Tolksdorf K, Horváth JK, Howard J, Pozo F, Gallardo V, Nonković D, Džiugytė A, Bossuyt N, Demuyser T, Duffy R, Luong Nguyen LB, Kislaya I, Martínez-Baz I, Gefenaite G, Knol MJ, Popescu C, Součková L, Simon M, Michelaki S, Reiche J, Ferenczi A, Delgado-Sanz C, Lovrić Makarić Z, Cauchi JP, Barbezange C, Van Nedervelde E, O'Donnell J, Durier C, Guiomar R, Castilla J, Jonikaite I, Bruijning-Verhagen PC, Lazar M, Demlová R, Wirtz G, Amerali M, Dürrwald R, Kunstár MP, Kissling E, Bacci S, Valenciano M; I-MOVE-COVID-19 hospital study team; VEBIS hospital study team; Members of the I-MOVE-COVID-19 and VEBIS hospital study teams (in addition to authors above). Rose AM, et al. Among authors: knol mj. Euro Surveill. 2023 Nov;28(47):2300187. doi: 10.2807/1560-7917.ES.2023.28.47.2300187. Euro Surveill. 2023. PMID: 37997665 Free PMC article.
Effectiveness of Immunization Products Against Medically Attended Respiratory Syncytial Virus Infection: Generic Protocol for a Test-Negative Case-Control Study.
van Roekel C, Poukka E, Turunen T, Nohynek H, Presser L, Meijer A, Heikkinen T, Kramer R, Begier E, Teirlinck AC, Knol MJ; PROMISE Investigators. van Roekel C, et al. Among authors: knol mj. J Infect Dis. 2024 Mar 1;229(Supplement_1):S92-S99. doi: 10.1093/infdis/jiad483. J Infect Dis. 2024. PMID: 37935046
156 results